Abstract: A torque fluctuation inhibiting device configured to inhibit torque fluctuations is disclosed. The torque fluctuation inhibiting device comprises a first rotor, a second rotor disposed to be rotatable relative to the first rotor, a centrifugal element, and a cam mechanism. The centrifugal element is configured to receive a centrifugal force generated by rotation of the first rotor. The centrifugal element is disposed to be movable with respect to the first rotor. The centrifugal element includes an engaging portion configured to be engage with the first rotor. The centrifugal element is formed by a plurality of components. The cam mechanism is configured to generate a circumferential force in movement of the centrifugal element and the circumferential force reduces relative displacement between the first rotor and the second rotor.

Abstract: A vibration reduction device for reducing a torsional vibration from an engine includes an input rotary part, an output rotary part, a damper part, a dynamic vibration absorbing device, and a torque limiting part. Torsional vibration is input to the input rotary part. The output rotary part is disposed to be relatively rotatable with respect to the input rotary part. The damper part is disposed between the input rotary part and the output rotary part and attenuates the torsional vibration input to the input rotary part. The dynamic vibration absorbing device absorbs the torsional vibration output from the damper part. The torque limiting part limits transmission of torque between the input rotary part and the output rotary part.

Abstract: A torque fluctuation inhibiting device for inhibiting torque fluctuations in a rotor to which a torque is inputted is disclosed. The torque fluctuation inhibiting device comprises a mass body, a plurality of drag mechanisms, and a restriction mechanism. The mass body is disposed to be rotatable with the rotor and to be rotatable relative to the rotor. Each of the plurality of drag mechanisms is for generating a circumferential force when a relative displacement is produced between the rotor and the mass body in a rotational direction. The circumferential force is directed to reduce the relative displacement. The restriction mechanism is for restricting actuation of one or more of the plurality of drag mechanisms.

Abstract: A torque fluctuation inhibiting device includes a first rotating body, a second rotating body, a centrifugal element, a support portion, and a displacement inhibiting mechanism. Torque is input to the first rotating body. The centrifugal element is subject to centrifugal force due to rotation of the first rotating body and moves in a direction different from a direction in which the centrifugal force acts. The support portion is provided in the first rotating body or the second rotating body and moveably guides the centrifugal element in the direction different from the direction in which the centrifugal force acts on the centrifugal element. The displacement inhibiting mechanism generates circumferential force which reduces a relative displacement of the first rotating body and the second rotating body when the centrifugal element moves in the direction different from the direction in which the centrifugal force acts on the centrifugal element.

Abstract: A vibration reduction device for reducing a torsional vibration from an engine includes an input rotary part, an output rotary part, a damper part, a dynamic vibration absorbing device, and a hysteresis torque generating part. The torsional vibration is input to the input rotary part. The output rotary part is disposed to be relatively rotatable with respect to the input rotary part. The damper part is disposed between the input rotary part and the output rotary part and attenuates the torsional vibration input to the input rotary part. The dynamic vibration absorbing device is for absorbing the torsional vibration output from the damper part. The hysteresis torque generating part is capable of generating a hysteresis torque when the damper part is in operation.

Abstract: A damper device is capable of attenuating fluctuations in torque. The damper device includes a first rotor and a second rotor rotatable relatively to the first rotor. The damper device also includes a plurality of elastic members elastically coupling the first rotor and the second rotor. The second rotor is rotatable relatively to the first rotor while held by the first rotor with use of the plurality of elastic members.

Abstract: A torque fluctuation inhibiting device includes plural centrifugal elements movable in a radial direction when receiving a centrifugal force generated in rotation of a rotor and a mass body. Each centrifugal element receives a rotational moment of inertia about an axis arranged in parallel to a rotational axis of the rotor when receiving the centrifugal force. When a relative displacement is produced between the rotor and the mass body in a rotational direction due to the centrifugal force acting on each centrifugal element, each cam mechanism converts the centrifugal force into a circumferential force directed to reduce the relative displacement. Support portions are provided on either the rotor or the mass body, and each makes contact with part of each centrifugal element when each centrifugal element receives the rotational moment of inertia. Each support portion supports each centrifugal element such that each centrifugal element is movable in the radial direction.

Abstract: A torque fluctuation inhibiting device includes a mass body. The mass body disposed to be rotatable with a rotor and be rotatable relatively to the rotor. Each of a plurality of centrifugal elements is radially movable by a centrifugal force that acts thereon in rotation of the rotor and the mass body. When a relative displacement is produced between the rotor and the mass body in a rotational direction while the centrifugal force is acting on the each of the plurality of centrifugal elements, each of a plurality of cam mechanisms converts the centrifugal force into a circumferential force directed to reduce the relative displacement. A plurality of restriction members allow the plurality of centrifugal elements to move in actuation of the plurality of cam mechanisms, and restrict the plurality of centrifugal elements from moving radially inward in non-actuation of the plurality of cam mechanisms.

Abstract: Isolated KIF20A-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce KIF20A-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.

Abstract: Isolated CDCA1-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce CDCA1-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.

Abstract: Isolated KIF20A-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce KIF20A-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.

Abstract: Isolated CDCA1-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce CDCA1-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.

Abstract: Isolated IMP-3-derived epitope peptides having Th1 cell inducibility are disclosed herein. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce IMP-3-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.

Abstract: Isolated GPC3-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce GPC3-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors including, for example, hepatocellular carcinoma and melanoma.

Abstract: According to the invention, by setting the linear thermal expansion amount when a mold made of a molding sand is heated from a room temperature to 1000° C. to be not more than 0.9%, and the ratio (D/d) between the diameter of a slump (D) and the diameter of a slump cone (d) in a slump test of the molding sand having a hardening agent kneaded to be not less than 1.65, a molding sand preferable for use in a mold produced using the self-hardening type of three dimensional laminate molding sand mold, having low thermal expansibility preventing occurrence of a veining defect, and capable of forming a large and complicated shape can be obtained.

Abstract: Isolated IMP-3-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. The peptides of the present invention can promiscuously bind to MHC class II molecules and induce IMP-3-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors expressing IMP-3.

Abstract: Isolated CDCA1-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce CDCA1-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.

Abstract: Isolated KIF20A-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce KIF20A-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.

Abstract: Isolated CDCA1-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce CDCA1-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.

Abstract: Isolated LY6K-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can be promiscuously bind to MHC class II molecules and induce LY6K-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.